Drug intelligence / Profile preview

ChloroStay

Development stage: Preclinical
Lead developer: Schottlander and Davis
Modality: Small Molecules
Administration: Topical

Overview

**ChloroStay** is a sustained-release, chlorhexidine-containing topical oral antiseptic mouthwash developed from work at Queen Mary University of London and manufactured/marketed by Schottlander. The product is supplied as two solutions that are mixed immediately before use to form tooth-adherent calcium chloride–chlorhexidine crystals, enabling low-dose chlorhexidine release for up to seven days. It is intended to support prevention and control of dental plaque and gingival inflammation, particularly in difficult-to-clean areas around teeth and fixed orthodontic appliances. ([schottlander.com](https://www.schottlander.com/products/general-product/chlorostay-7-day-mouthwash/))

Brand names: ChloroStayChloroStay 7-Day MouthwashChloroStay7-Day MouthwashChloroStay-7-Day Mouthwash

Beyond the preview

Go deeper on ChloroStay.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChloroStay.

Explore the full profile